HANSIZHUANG (recombinant humanised anti-PD-1 monoclonal antibody injection, generic name: serplulimab injection) is the first innovative monoclonal antibody developed by Henlius. Up to date, 1 indication is approved for marketi...
ASTRUM-005研究是复宏汉霖自主研发的抗PD-1单抗H药 汉斯状®(斯鲁利单抗)联合化疗一线治疗广泛期小细胞肺癌(ES-SCLC)的Ⅲ期临床研究,2022年ASCO年会程颖教授首次报告结果后,引起了全球同行的广泛关注,而今再度登上国际顶级学术舞台,...
Host / Isotype Mouse / IgG1 Class Monoclonal Type Antibody Full Name CD274 molecule Synonyms CD274, PD-L1, PD L1, hPD-L1, B7-H1 Calculated Molecular Weight 290 aa, 33 kDa Observed Molecular Weight 45-50 kDa, 33 kDa GenBank Accession Number BC074984 Gene Symbol PD-L1...
Finally, leading gutter replacement companies will give you value for your money. It doesn’t matter how much you are willing to spend for quality gutter replacement, at the end of the day you will be able to land a provider that gives you full value for your money. Avail Of The Best ...
Ivonescimab is engineered by fusing the antigen-binding fragment of an anti-PD-1 monoclonal antibody in a single-chain variable fragment (scFv) format with a full anti-VEGF monoclonal antibody. This creates a novel tetravalent molecule that integrates two well-established oncology mechanisms: anti-...
Cat No.66248-1-Ig 浓度:2000 ug/ml 库存:现货 点击咨询售前客服 点击咨询售后客服 humanWB,IHC,IF ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. See more citations ICOSLG/B7-H2/CD275 Polyclonal antibody ...
D661077-00011 MG预计30日内发货385385 产品描述 概述 Synthetic peptide corresponding to a region derived from 270-284 amino acids of human Programmed cell death 1 属性 Full nameProgrammed cell death 1 SynonymsPD1, PD-1, CD279, SLEB2, hPD-1, hPD-l ...
LG product service and support Get support Learn More
sheet.Range(sheet.cells(rowsNum-colsNum+1,1),sheet.cells(rowsNum,7)).Font.Size = 10 rowsNum = rowsNum + 2 Output "FullDescription: " + tab.Name End If End Sub '--- ' Show List Of Table '--- Sub ShowTableList(mdl, SheetList) '...
2022年12月27日, 复宏汉霖 (02696.HK)宣布与 复星医药 (600196.SH,02196.HK)达成合作,授予其在美国对复宏汉霖自主开发的抗PD-1单抗 H药 汉斯状®(斯鲁利单抗)包括广泛期小细胞肺癌(ES-SCLC)在内的适应症进行独家商业化的权益。根据协议条款, 复星医药 将负责